Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib.

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2024-11-21 DOI:10.1111/ajd.14386

Harmeet K Bhullar, Friyana Bhabha, Chris McCormack, H Miles Prince

引用次数: 0

Abstract

Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.

查看原文本刊更多论文

阿卡鲁替尼使斯内登-威尔金森病的皮肤症状完全缓解。

斯内登-威尔金森（SW）病是一种罕见的疾病，通常发生在单克隆免疫球蛋白的背景下，治疗方案尚未得到充分研究。我们在此介绍一例 65 岁女性 SW 患者，她患有淋巴浆细胞性淋巴瘤（LPL）并伴有 IgA 副蛋白，但病情并不严重，在服用布鲁顿酪氨酸激酶抑制剂（BTKi）阿卡鲁替尼后，皮肤症状完全缓解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.